India's Bharat Biotech pursues Covid-19 jabs approval in over 40 countries | Inquirer News

India’s Bharat Biotech pursues Covid-19 jabs approval in over 40 countries

/ 03:34 PM February 18, 2021

India's Bharat Biotech pursues Covid-19 jabs approval in over 40 countries

FILE PHOTO: Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech’s COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi

BENGALURU India’s Bharat Biotech is in the process of filing regulatory documents for approval of its Covid-19 vaccine, COVAXIN, in more than 40 countries, the company told Reuters late on Wednesday.

“We have submitted our documentation in Brazil and other countries and await their approval. We plan to export several million doses to Brazil,” the company said in an emailed statement. “Pricing of COVAXIN for international markets will be based upon supply timelines, purchase commitments, and procurement volumes,” it added.

Article continues after this advertisement

Bharat Biotech, which last Tuesday had told Reuters it may export doses of COVAXIN to Brazil and the United Arab Emirates by the end of the week, did not name other countries and did not give exact figures on doses it expects to export.

FEATURED STORIES

The company has also entered into an agreement with U.S. drug developer Ocugen Inc for the commercialization of COVAXIN in the United States, which has seen the most number of infections in the world.

COVAXIN is one of the two vaccines approved for emergency use in India, though efficacy data from its late-stage trial is yet to be published.

Article continues after this advertisement

Bharat Biotech expects results from an ongoing trial involving 25,800 participants in India only by March, though the country’s drug regulator has called the vaccine safe and effective amid criticism from some doctors and health experts.

Article continues after this advertisement

COVAXIN is currently being used by India in its vaccination campaign, which has already covered more than 9 million health workers and aims to cover 300 million people by August. Bharat Biotech has supplied 5.5 million doses to the government and will sell an additional 4.5 million doses.

India, with nearly 11 million coronavirus cases, has the second-highest number of infections in the world, though some experts believe the worst of the disease has passed in the country.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Coronavirus, Covaxin, COVID-19, Health, India, pandemic, SARS-CoV-2, vaccine, Virus

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.